Dianthus Therapeutics, Inc. (DNTH) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production,...
Is Dianthus Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Dianthus Therapeutics, Inc. (DNTH) trades at $82.25 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Dianthus Therapeutics, Inc.
Market cap $5B · 52 weeks $33 – $116 (29 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS -$0.94 · Closing price, Nov 2 · accounts published Aug 4.
- Valuation: P/Sales 640× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 4.7 %, fails.
- Market cap / Cash 7.7×, fails.
- Cash Runway 38 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $3.41, info.
Against its peers (reference peers) — Dianthus Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -18.5 %; $4.6B. PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.9×; ROIC 5.7 %; $5.1B), Arcutis Biotherapeutics, Inc. (P/E 150×; EV/EBITDA 94.7×; ROIC 9.9 %; $3.9B), Acadia Pharmaceuticals Inc. (P/E 9.2×; EV/EBITDA 27.7×; ROIC 6.2 %; $3.5B).
Profitability
| Return on Equity | -3.51% |
| Return on Invested Capital | -18.47% |
| Return on Assets | -2.47% |
| Gross Margin | 96.01% |
| Operating Margin | -11,441.39% |
| Net Margin | -1,570.85% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 26.10 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 23.77 |
Price Performance
| 1 month | -6.76% |
| 3 months | -26.89% |
| Year-to-date | +99.59% |
| 1 year | +141.70% |
| 3 years | +585.42% |
| 5 years | -38.29% |
Related companies: IMVT · VERA · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DNTH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks